Previous 10 | Next 10 |
Author technical setup chart Sangamo ( SGMO ) is well-situated for the remainder of 2020 after the Biogen ( BIIB ) collaboration. 1Q20 cash plus the Biogen proceeds brought available cash to over $700 million. Sangamo C20 guidance for non-GAAP operating expenses (opex less stock compensati...
Between erratic market conditions, risk-fraught clinical trials, and unpredictable drug development pipelines, biotech investors know that with some stocks, discretion is the better part of valor. Nonetheless, July is a critical month for several leading biotech companies, and there's a lot that...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway. Jason Fontenot, Senior Vice President, Cell T...
So far, so good for Pfizer (NYSE: PFE) and Sangamo Therapeutics ' (NASDAQ: SGMO) gene therapy candidate, giroctocogene fitelparvovec, which the healthcare companies are developing for patients with hemophilia A. None of the five patients in the phase 1/2 clinical trial treated at the h...
Pfizer ( PFE -0.8% ) and collaborator/licensor Sangamo Therapeutics ( SGMO +0.4% ) announce updated data from an open-label, 11-subject Phase 1/2 clinical trial evaluating gene therapy giroctocogene fitelparvovec (SB-525, or PF-07055480) in patients with severe hemophilia A. The result...
— Dosing of the first patient in the pivotal Phase 3 study anticipated in second half of 2020 — Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of gi...
Biogen (NASDAQ: BIIB) hasn't been the world's most reliable biotech stock over the past five years. Major setbacks in its Alzheimer's disease drug-development pipeline have crimped growth, and the withdrawal from the market of its multiple sclerosis drug Zinbryta caused potential investors...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET. The presentation will be webcast live and may be accessed via a link on the Sangamo Therap...
The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET. The audio presentation will be webcast live and may be accessed via a link on the San...
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
2024-05-15 13:30:05 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for SGMO on May 15, 2024 11:01AM ET. The previous analyst recommendation was Underperform. SGMO was trading at $0.5901 at issue of the analyst recommendation. The overall analyst consensus ...
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrie...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from...